JNJ-40411813

DB12059InvestigationalSmall molecule

JNJ-40411813 has been used in trials studying the treatment and basic science of Confusion, Schizophrenia, Perceptual Disorders, and Major Depressive Disorder.

Mechanism: Pharmacologically active on Metabotropic glutamate receptor 2
Curator reviewed
Formula / weight: C₂₀H₂₅ClN₂O · 344.88 g/mol (avg)
Code names: JNJ-40411813

Resolves to

Compound

UNII612BYT76F3CAS1127498-03-6ChEMBLCHEMBL3337527PubChem25195461

Structure

InChIKeyHYOGJHCDLQSAHX-UHFFFAOYSA-NSMILESCCCCN1C=CC(N2CCC(CC2)C2=CC=CC=C2)=C(Cl)C1=O

Targets

Q14416GRM2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with JNJ-40411813, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account